FDA advisers endorse Eli Lilly’s early-stage Alzheimer’s drug donanemab
WEBJun 11, 2024 · On Monday, a panel of independent advisers to the US Food and Drug Administration voted to endorse Eli Lilly’s drug donanemab, a monoclonal antibody designed to slow the progression of...
New Drug Approved for Early Alzheimer’s - The New York Times
WEBJuly 2, 2024. The Food and Drug Administration on Tuesday approved a new drug for Alzheimer’s disease, the latest in a novel class of treatments that has been greeted with hope,...
News Release - Eli Lilly and Company
WEBJul 2, 2024 · Kisunla™ (donanemab-azbt) (pronounced kih-SUHN-lah) is an amyloid-targeting treatment for people with mild cognitive impairment (MCI) as well as people with mild dementia stage of early symptomatic Alzheimer's …
Experimental Alzheimer's drug donanemab outperforms Leqembi in ... - NPR
WEBJul 17, 2023 · In a large study, the experimental drug donanemab slowed the progression of Alzheimer's by about 35%. That's slightly better than the drug Leqembi, which was fully approved by the FDA on July 6.
FDA approves a second Alzheimer's drug, Eli Lilly's Kisunla - AP News
WEBJul 2, 2024 · The FDA approved Kisunla, known chemically as donanemab, based on results from an 18-month study in which patients given getting the treatment declined about 22% more slowly in terms of memory and cognitive ability than those who received a dummy infusion.
FDA approves donanemab, Eli Lilly’s treatment for early ... - CNN
WEBJul 2, 2024 · The US Food and Drug Administration on Tuesday approved donanemab, a monoclonal antibody designed to slow the progression of early symptomatic Alzheimer’s disease.
News Release - Eli Lilly and Company
WEBMay 3, 2023 · Donanemab treatment slowed clinical decline by 35% compared to placebo, and resulted in 40% less decline on the ability to perform activities of daily living. Over half of all participants completed their course of treatment by 12 months
FDA approves new Alzheimer's treatment, donanemab from Eli Lilly - CBS News
WEBJul 3, 2024 · The Food and Drug Administration approved a new Alzheimer's treatment called donanemab on Tuesday, clearing the way for the third addition to a new class of drugs aimed at slowing the brain's...
Alzheimer’s drug donanemab helps most when taken at earliest
WEBJul 17, 2023 · Like many others in the newest generation of Alzheimer’s drugs, donanemab is a monoclonal antibody that targets amyloid, a sticky, neuron-damaging protein, in the brains of people with dementia.
Eli Lilly expects FDA decision on Alzheimer's treatment donanemab …
WEBJul 17, 2023 · An FDA approval of Eli Lilly's donanemab would expand the treatment options for the more than 6 million Americans of all ages who have Alzheimer's, the fifth-leading cause of death for adults...